首页> 美国卫生研究院文献>BMC Biotechnology >Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists
【2h】

Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists

机译:抗核酸酶的免疫刺激性磷酸二酯CpG寡脱氧核苷酸作为人类Toll样受体9激动剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundUnmethylated cytosine-guanine (CpG) motif-containing oligodeoxynucleotides (ODNs) have been well characterized as agonists of Toll-like receptor 9 (TLR9). ODNs with a phosphorothioate (PTO) backbone have been studied as TLR9 agonists since natural ODNs with a phosphodiester (PD) backbone are easily degraded by a serum nuclease, which makes them problematic for therapeutic applications. However, ODNs with a PTO backbone have been shown to have undesirable side effects. Thus, our goal was to develop nuclease-resistant, PD ODNs that are effective as human TLR9 (hTLR9) agonists.
机译:背景技术含有未甲基化的胞嘧啶-鸟嘌呤(CpG)基序的寡脱氧核苷酸(ODN)已被很好地表征为Toll样受体9(TLR9)的激动剂。已经研究了具有硫代磷酸酯(PTO)骨架的ODN作为TLR9激动剂,因为具有磷酸二酯(PD)骨架的天然ODN容易被血清核酸酶降解,这使其成为治疗应用中的难题。但是,具有PTO主干的ODN已显示出不良副作用。因此,我们的目标是开发能有效作为人类TLR9(hTLR9)激动剂的抗核酸酶的PD ODN。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号